Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"phase II trial"”.
-
A BIOMARKER ENRICHMENT PHASE II TRIAL OF 177LU-DOTATATE IN METASTATIC NASOPHARYNGEAL CANCER WITH A SAFETY RUN-IN
… radioconjugate in PET-CT scanning in a clinical trial of NPC patients (NCT03670342). We also found that SSTR2 expression is induced by the Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1) via the NF-κB pathway and SSTR2 expression can be seen in vitro and in vivo in certain other EBV …
-
Targeting Epigenetic Regulators For The Treatment of Diffuse Large B-Cell Lymphoma
… to a 60% Objective Response Rate (ORR) in Phase I clinical trials, Phase II trial results for the EZH2 inhibitor EPZ-6438 reported an attenuation of response. Mechanisms contributing to lymphoma cell survival and growth after EZH2 ablation are poorly studied. In EZH2-mutant cells, we found …
-
EGFR in Early Non-small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial
… their role in early disease, we implemented a phase II trial of neoadjuvant gefitinib in clinical stage I NSCLC. Tumour shrinkage was seen in 43% of patients, with 11% achieving RECIST partial response (PR). Analysis of molecular markers showed EGFR TKD mutations in 17% of cases, being the only …
-
Bayesian Adaptive Designs For Proof-of-Concept Trials and Platform Trials
… the traditional drug development paradigm in phase II trials becomes increasingly inefficient due to its slow progress, high cost, and high failure rate. Fitting one standard strategy to all different trials also harms its reliability in decision-making because it doesn’t fully use all …
-
Phase II Trials Powered to Detect Activity in Tumor Subsets with Retrospective (or Prospective) Use of Predictive Markers
Classical phase II trial designs assume a patient population with a homogeneous tumor type and yield an estimate of a stochastic probability of tumor response. Clinically, however, oncology is moving towards identifying patients who are likely to respond to therapy using tumor subtyping based upon …
-
Targeting Apoptotic Pathways to Overcome Drug Resistance In Acute Myeloid Leukemia
… and forms the concept for an international phase II trial in AML.</p>
-
Bayesian Adaptive Designs For Early Phase Clinical Trials
… focuses mainly on Bayesian adaptive designs for phase I and phase II clinical trials. It includes three specific topics: <strong>(1)</strong> proposing a novel two-dimensional dose-finding algorithm for biological agents, <strong>(2)</strong> developing Bayesian adaptive screening designs to …
-
Hochdosis-Chemotherapie gefolgt von einer myeloablativen Hochdosis-Radioimmuntherapie (HD-RAIT) mit Iod-131-Rituximab und peripherer Stammzelltransplantation (SCTx) bei primär refraktären und rezidivierten Non-Hodgkin-Lymphomen
Einleitung: Ziel der Phase-II-Studie war die Überprüfung der Machbarkeit eines Tandem-Konzeptes mit einer initialen Hochdosistherapie mit BEAM mit SCTx gefolgt von einer myeloablativen HD-RAIT mit Iod-131-Rituximab und SCTx. Methoden: In die Studie eingeschlossen wurden 19 Patienten mit …